In conclusion, our results demonstrate that FPR2 has anti-inflammatory roles in the liver and that its sex-specific expression is closely related to sex disparities in NAFLD/NASH development. The gene discussed is FPR2; the disease is metabolic dysfunction-associated steatotic liver disease.